Readout of White House Meeting with Overdose Reversal Medication Manufacturers

Manufacturers announce capacity to produce additional 25 million doses to help saturate hardest-hit communities, along with new donations to help strengthen public awareness campaigns

Today, White House Office of National Drug Control Policy Director Dr. Rahul Gupta and White House Domestic Policy Council Advisor Neera Tanden hosted a second convening with U.S. drug manufacturers who make FDA-approved opioid overdose reversal medications. During the meeting, senior officials highlighted the Biden-Harris Administration’s guiding principles on expanding access to lifesaving overdose reversal medications. Officials and manufacturers focused on the importance of saturating communities and populations at high-risk of overdose with opioid overdose reversal medications, and increasing public awareness on the dangers of fentanyl.

To help meet the needs of the hardest hit communities across the country, manufacturers announced they are building more capacity to produce opioid overdose reversal medications, resulting in the potential for an additional 25 million doses in 2025 to help saturate areas with high numbers and rates of opioid overdose. This critical increase in production, along with new opportunities to purchase opioid overdose reversal medications over-the-counter, will increase access to these life-saving medications for more people.

Seven manufacturers also announced they will donate funds to help expand the geographic reach of the Real Deal on Fentanyl campaign, which educates young people on the dangers of fentanyl and the lifesaving effects of overdose reversal medications. These funds will also support the development of new resources in both English and Spanish to reach young people who may be at risk for overdose.

Senior White House officials also called on manufacturers to support the recently launched White House Challenge to Save Lives from Overdose, a nationwide call-to-action to leaders across sectors to increase training on and access to overdose reversal medications.

Participants included:

• White House Office of National Drug Control Policy Director Dr. Rahul Gupta
• White House Domestic Policy Council Advisor Neera Tanden
• Amneal Pharmaceuticals, LLC
• Emergent BioSolutions, Inc.
• Harm Reduction Therapeutics, Inc.
• Hikma Pharmaceuticals, PLC
• Indivior, PLC
• Padagis, LLC
• Pfizer, Inc.
• Teva Pharmaceutical Industries, LTD

###